Ventyx Biosciences (VTYX) Rethinks Anti-Inflammatory Pipeline After Promising Phase 2 Results for VTX3232 [Yahoo! Finance]
Ventyx Biosciences, Inc. (VTYX)
Company Research
Source: Yahoo! Finance
key inflammatory biomarkers such as hsCRP, IL-6, and Lp(a) in patients with obesity and cardiovascular risk factors. These findings highlight the potential of VTX3232 as an oral, once-daily anti-inflammatory therapy, both as a monotherapy and in combination with established GLP-1 treatments like semaglutide. We'll explore how the substantial reduction in inflammatory risk factors may influence Ventyx Biosciences' investment narrative in the coming period. Uncover the next big thing with financially sound penny stocks that balance risk and reward What Is Ventyx Biosciences' Investment Narrative? For anyone looking at Ventyx Biosciences as a potential investment, the broader story rests on belief in the company's ability to move its lead drug VTX3232 further along the pipeline, and to ultimately prove both clinical and commercial value in a field crowded with high expectations. The recent Phase 2 results showing substantial reductions in inflammatory biomarkers mark a major st
Show less
Read more
Impact Snapshot
Event Time:
VTYX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VTYX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VTYX alerts
High impacting Ventyx Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
VTYX
News
- Ventyx Provides Clinical and Corporate UpdatesGlobeNewswire
- Ventyx Biosciences to Participate in the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswire
- Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference in LondonGlobeNewswire
- Ventyx Biosciences: Why Caution Should Remain [Seeking Alpha]Seeking Alpha
- Ventyx Biosciences (NASDAQ:VTYX) had its price target raised by analysts at Canaccord Genuity Group Inc. from $14.00 to $16.00. They now have a "buy" rating on the stock.MarketBeat
VTYX
Earnings
- 11/6/25 - Beat
VTYX
Sec Filings
- 11/26/25 - Form SCHEDULE
- 11/19/25 - Form 4
- 11/19/25 - Form 4
- VTYX's page on the SEC website